PSA and Second-Line Therapy of Hormone Refractory Prostate Carcinoma

Publisher： Karger

E-ISSN： 1423-0399|66|3|131-134

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.66, Iss.3, 2001-04, pp. : 131-134

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study

By  

Oncology Research and Treatment, Vol. 32, Iss. 3, 2009-02 ,pp. : 99-102

Karger

Access to resources Recommend Favorite

Gemcitabine Monotherapy as Second-Line Treatment in Cisplatin-Refractory Transitional Cell Carcinoma – Prognostic Factors for Response and Improvement of Quality of Life

By  

Oncology Research and Treatment, Vol. 25, Iss. 1, 2002-03 ,pp. : 47-52

Karger

Access to resources Recommend Favorite

Factors associated with second‐line triplet therapy in routine care in relapsed/refractory multiple myeloma

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 43, Iss. 1, 2018-02 ,pp. : 45-51

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Outcome of Paclitaxel and Carboplatin as Second-Line Chemotherapy for Advanced Urothelial Carcinoma Resistant to First-Line Therapy with Gemcitabine and Cisplatin

By  

Urologia Internationalis, Vol. 92, Iss. 2, 2013-11 ,pp. : 180-185

Karger

Access to resources Recommend Favorite

Second-Line Antiandrogen Therapy in Japanese Men with Advanced Prostate Cancer Relapsed after Primary Combined Androgen Blockade: Who Will Benefit from Second-Line Hormonal Therapy?

By  

Urologia Internationalis, Vol. 85, Iss. 4, 2010-08 ,pp. : 491-497

Karger

Access to resources Recommend Favorite